Ocular delivery of pRNA nanoparticles: Distribution and clearance after subconjunctival injection

Pharmaceutical Research

Volumn 31, Issue 4, 2014, Pages 1046-1058

  Feng, Liang ^a   Li, S Kevin ^a   Liu, Hongshan ^b   Liu, Chia Yang ^b   Lasance, Kathleen ^a   Haque, Farzin ^c   Shu, Dan ^c   Guo, Peixuan ^c  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

double stranded RNA; ocular delivery; pRNA nanoparticle; subconjunctival; topical

Indexed keywords

ALEXA647 DYE; DOUBLE STRANDED DNA; DYE; NANOPARTICLE; PRNA 3WJ; PRNA X; UNCLASSIFIED DRUG; RNA; TERMINAL PROTEIN, BACILLUS PHAGE PHI29; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONJUNCTIVA; CORNEA; DRUG DELIVERY SYSTEM; FEMALE; FLUORESCENCE MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCLERA; ANIMAL; C57BL MOUSE; DRUG EFFECTS; EYE; METABOLISM; PROCEDURES; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; CONJUNCTIVA; DRUG DELIVERY SYSTEMS; EYE; FEMALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; RNA; VIRAL PROTEINS;

EID: 84897072221     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1226-x     Document Type: Article

References (46)

1. Fattal E, Bochot A. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv Drug Deliv Rev. 2006;58:1203-23.
2. Pieramici DJ, Rabena MD. Anti-VEGF therapy: comparison of current and future agents. Eye (Lond). 2008;22:1330-6.
3. de Smet MD, Meenken CJ, van den Horn GJ. Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul Immunol Inflamm. 1999;7:189-98.
4. Ng EW, Shima DT, Calias P, Cunningham Jr ET, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006;5:123-32.
5. FDA. A safety and efficacy study of E10030 (anti-PDGF pegylated aptamer) plus Lucentis for neovascular age-related macular degeneration, Clinicaltrials.gov, 2012, NCT01089517.
6. Lee SS, Robinson MR. Novel drug delivery systems for retinal diseases. A review. Ophthalmic Res. 2009;41:124-35.
7. Guo P, Zhang C, Chen C, Garver K, Trottier M. Inter-RNA interaction of phage phi29 pRNA to form a hexameric complex for viral DNA transportation. Mol Cell. 1998;2:149-55.
8. Guo P. The emerging field of RNA nanotechnology. Nat Nanotechnol. 2010;5:833-42.
9. Guo P, Haque F, Hallahan B, Reif R, Li H. Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. Nucleic Acid Ther. 2012;22:226-45.
10. Haque F, Shu D, Shu Y, Shlyakhtenko LS, Rychahou PG, Evers BM, et al. Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers. Nano Today. 2012;7:245-57.
11. Liu J, Guo S, Cinier M, Shlyakhtenko LS, Shu Y, Chen C, et al. Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging. ACS Nano. 2011;5:237-46.
12. Shu D, Shu Y, Haque F, Abdelmawla S, Guo P. Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nat Nanotechnol. 2011;6:658-67.
13. Macha S, Mitra AK. Ocular pharmacokinetics in rabbits using a novel dual probe microdialysis technique. Exp Eye Res. 2001;72:289-99.
14. Berezovsky DE, Patel SR, McCarey BE, Edelhauser HF. In vivo ocular fluorophotometry: delivery of fluoresceinated dextrans via transscleral diffusion in rabbits. Invest Ophthalmol Vis Sci. 2011;52:7038-45.
15. Li SK, Lizak MJ, Jeong EK. MRI in ocular drug delivery. NMR Biomed. 2008;21:941-56.
16. Kim SH, Lutz RJ, Wang NS, Robinson MR. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res. 2007;39:244-54.
17. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58:1131-5.
18. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26:1197-216.
19. Maurice D. Review: practical issues in intravitreal drug delivery. J Ocul Pharmacol Ther. 2001;17:393-401.
20. Dastjerdi MH, Sadrai Z, Saban DR, Zhang Q, Dana R. Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci. 2011;52:8718-23.
21. Bejjani RA, BenEzra D, Cohen H, Rieger J, Andrieu C, Jeanny JC, et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis. 2005;11:124-32.
22. Bourges JL, Gautier SE, Delie F, Bejjani RA, Jeanny JC, Gurny R, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci. 2003;44:3562-9.
23. Andrieu-Soler C, Halhal M, Boatright JH, Padove SA, Nickerson JM, Stodulkova E, et al. Single-stranded oligonucleotide-mediated in vivo gene repair in the rd1 retina. Mol Vis. 2007;13:692-706.
24. Chopra P, Hao J, Li SK. Iontophoretic transport of charged macromolecules across human sclera. Int J Pharm. 2010;388:107-13.
25. Wen H, Hao J, Li SK. Characterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab. J Pharm Sci. 2013;102:892-903.
26. Demetriades AM, Deering T, Liu H, Lu L, Gehlbach P, Packer JD, et al. Trans-scleral delivery of antiangiogenic proteins. J Ocul Pharmacol Ther. 2008;24:70-9.
27. Amaral J, Fariss RN, Campos MM, Robison Jr WG, Kim H, Lutz R, et al. Transscleral-RPE permeability of PEDF and ovalbumin proteins: implications for subconjunctival protein delivery. Invest Ophthalmol Vis Sci. 2005;46:4383-92.
28. Kim SH, Galban CJ, Lutz RJ, Dedrick RL, Csaky KG, Lizak MJ, et al. Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging. Invest Ophthalmol Vis Sci. 2007;48:808-14.
29. Lee SJ, He W, Robinson SB, Robinson MR, Csaky KG, Kim H. Evaluation of clearance mechanisms with transscleral drug delivery. Invest Ophthalmol Vis Sci. 2010;51:5205-12.
30. Li SK, Molokhia SA, Jeong EK. Assessment of subconjunctival delivery with model ionic permeants and magnetic resonance imaging. Pharm Res. 2004;21:2175-84.
31. Lee TW, Robinson JR. Drug delivery to the posterior segment of the eye II: development and validation of a simple pharmacokinetic model for subconjunctival injection. J Ocul Pharmacol Ther. 2004;20:43-53.
32. Kim SH, Csaky KG, Wang NS, Lutz RJ. Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging. Pharm Res. 2008;25:512-20.
33. Kim H, Robinson MR, Lizak MJ, Tansey G, Lutz RJ, Yuan P, et al. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci. 2004;45:2722-31.
34. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol. 2005;57:1555-63.
35. Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis. 2008;14:150-60.
36. Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012;57:415-29.
37. Ishikawa S, Hirata A, Nakabayashi J, Iwakiri R, Okinami S. Neuroprotective effect of small interfering RNA targeted to caspase-3 on rat retinal ganglion cell loss induced by ischemia and reperfusion injury. Curr Eye Res. 2012;37:907-13.
38. Williams KA, Klebe S. Gene therapy for corneal dystrophies and disease, where are we? Curr Opin Ophthalmol. 2012;23:276-9.
39. Henry SP, Miner RC, Drew WL, Fitchett J, York-Defalco C, Rapp LM, et al. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication. Invest Ophthalmol Vis Sci. 2001;42:2646-51.
40. Li W, Szoka Jr FC. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res. 2007;24:438-49.
41. Abdelmawla S, Guo S, Zhang L, Pulukuri SM, Patankar P, Conley P, et al. Pharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic delivery. Mol Ther. 2011;19:1312-22.
42. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6:443-53.
43. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;8:173-84.
44. Seth S, Johns R, Templin MV. Delivery and biodistribution of siRNA for cancer therapy: challenges and future prospects. Ther Deliv. 2012;3:245-61.
45. Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A. 2007;104:12982-7.
46. Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Basile AS, Klamerus KJ, et al. Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study). Invest Ophthalmol Vis Sci. 2012;53:7666-74.